Research and Markets: In February 2008, a Dutch Court Ruled against Us Drug-Maker Pfizer in a Court Case Regarding the Patent on Atorvastatin

DUBLIN, Ireland–(EMWNews)–Research and Markets (http://www.researchandmarkets.com/research/c55724/netherlands_pharma)

has announced the addition of the “Netherlands Pharmaceuticals and

Healthcare Report Q2 2008” report to their offering.

The Netherlands Pharmaceuticals and Healthcare Report provides

independent forecasts and competitive intelligence on Netherlands

pharmaceuticals and healthcare industry.

Growth will be far from impressive for the drug market in the

Netherlands over the forecast period, although, in many ways this

reflects the general sluggishness seen in mature markets. BMI expects

the market to reach a value of US$7.06bn in 2012, representing a

compound annual growth rate (CAGR) of 2.08%. Growth will be strongest in

the generics market but should also be reasonable for consumer health

products as these medicines benefit from government liberalisation

policies.

The generics sector, however, will be negatively impacted by the new

transition agreement regarding pharmaceutical prices that has come into

effect. In January 2008, the price of generic medicines was reduced by

10%. BMI has factored this decrease into our forecasts and believes that

the generics market will reach a value of US$1.28bn by 2012. In

addition, medicines whose patents expire in 2008 will see price cuts of

50%. The Dutch Pharmacy Association, KNMP, claims that the plans are

designed to keep the cost of medicines down. Also, they are designed to

help transform the pharmaceutical market from being supply-based to

being demand-based.

In terms of company activity, the sector has been quiet after last year

saw US drug-maker Schering-Plough acquire Organon, the pharmaceuticals

division of Dutch industrial conglomerate Akzo Nobel for EUR11bn

(US$14.5bn). However, in February 2008, a Dutch court ruled against US

drug-maker Pfizer in a court case regarding the patent on atorvastatin,

the key ingredient in cholesterol reducing drug Lipitor is invalid. This

is a severe blow for Pfizer, as it could open the door for generic

competition for its bestselling drug.

Meanwhile, recent attacks by animal extremists in the Netherlands have

forced a local company to pull out of a life sciences project. BMI

believes that the latest problems in the Netherlands, if sustained, will

have a negative impact on the country’s Business Environment Rating. The

Netherlands has a respected regulatory system, with an average score of

eight across our three main indicators, but we will downgrade the scores

if intimidation of the research sector is permitted to continue.

Key Topics Covered:

Executive Summary

Netherlands Pharmaceuticals And Healthcare Industry

Pharmaceutical Business Environment Ratings

Table: Western European Pharmaceutical Business Environment Ratings

Limits To Potential Returns

Risks To Realisation Of Returns

Market Summary

Regulatory Regime

Intellectual Property Developments

Pricing And Reimbursement

OTC Medicines

Industry Developments

Healthcare Sector

Healthcare Insurance

Table: Key Points – Dutch Health Insurance Act, January 1 2006

Health Profile

Pharmaceuticals Sector

Recent Domestic Companies’ Activities

Recent Foreign Companies’ Activities

Research And Development Sector

Industry Forecast Scenario

Overall Market Forecast

Table: The Netherlands Drug Market Forecast Indicators

Key Growth Factors – Industry

Table: Netherlands Health Expenditure Indicators

Key Growth Factors – Macroeconomic

Table: Netherlands – Macroeconomic Forecasts

Patented Market Forecast

Table: The Netherlands’ Patented Drug Market

Forecast Indicators (US$mn unless otherwise stated)

Over-The-Counter Market Forecast

Table: The Netherlands OTC Drugs Market Forecast Indicators (US$mn

unless otherwise stated)

Generics Forecasts

Table: The Netherlands’ Generics And Branded

Market Forecast Indicators

Export/Import Forecasts

Table: The Netherlands’ Pharmaceutical Trade

Forecast Indicators (US$mn)

Key Risks To our Forecast Scenario

Competitive Landscape

Company Profiles

Leading Multinational Manufacturers

– Merck & Co

– Pfizer

– GlaxoSmithKline (GSK)

– Sanofi-Aventis

– Novartis

Indigenous Manufacturers

– Akzo Nobel

– DSM

– Qiagen

– Pharming Group

– Crucell

BMI Forecast Modelling

How We Generate Our Industry Forecasts

Pharmaceutical Industry

Pharmaceutical Business Environment Ratings Methodology

Ratings Overview

Table: Pharmaceutical Business Environment Indicators

Weighting

Table: Weighting Of Components

Sources

For more information visit http://www.researchandmarkets.com/research/c55724/netherlands_pharma

Major Newsire & Press Release Distribution with Basic Starting at only $19 and Complete OTCBB / Financial Distribution only $89

Get Unlimited Organic Website Traffic to your Website 
TheNFG.com now offers Organic Lead Generation & Traffic Solutions